Kerecis has added Shield Spiral to its Kerecis Shield silicone fish-skin combination product range to offer advanced customisable wound care solutions.
The Iceland-based firm develops methods utilising sustainably sourced fish skin and fatty acids for cellular therapy, tissue regeneration, and protection.
The patented fish-skin graft and silicone combination features perforated fenestration marks arranged in a spiral pattern to facilitate simple customisation. This can allow the graft to fit different wound sizes precisely.
From 30mm, the graft can be reduced to 15mm by removing the 2mm outer spiral sections and cutting to the required dimensions.
According to Kerecis, this design offers flexibility and accuracy during treatment.
Shield Spiral offers graft protection similar to any other Kerecis Shield product line products.
Its porous silicon contact layer allows optimal integration with the wound bed, promoting effective healing.
Kerecis founder and CEO Fertram Sigurjonsson said: “At Kerecis, we continue to be inspired by the insights of the doctors that use the intact fish-skin every day.
“The development of Shield Spiral is a direct result of feedback from doctors that asked for a product that could be shaped faster and easier to the size of smaller wounds.”
Shield Spiral is part of the Kerecis Shield product family, which already includes Shield Adhesive and Shield Standard.
These products are formulated for the treatment of both chronic and acute wounds, including diabetic foot ulcers, pressure ulcers, vascular ulcers, post-Mohs surgical wounds, and draining wounds.
The grafts incorporate essential natural skin elements and are fenestrated to facilitate proper wound drainage, ensuring optimal moisture levels at the wound bed, Kerecis said.
The firm’s patented products, when grafted onto damaged human tissue or implanted, support the body’s natural healing and regenerative processes.
Currently, Kerecis is said to be the only approved manufacturer globally of medical devices containing intact fish skin.
Its product portfolio includes SurgiBind/SurgiClose for reconstructive surgery in hospital operating rooms, GraftGuide for burn centres, and MariGen and Shield for chronic wounds.
